(5Z,12E,14E)-11-Oxoprosta-5,9,12,14-tetraen-1-oic acid(CAS: 87893-55-8)

The regulatory guidelines for (5Z,12E,14E)-11-Oxoprosta-5,9,12,14-tetraen-1-oic acid (CAS: 87893-55-8) include GHS classification, REACH regulations, and FDA/EPA requirements. It is classified as a Hazardous Substance under GHS and must comply with REACH for registration, evaluation, authorization, and restriction of chemicals. Specific use applications may require additional permits and safety data sheets (SDS).

There are several alternatives to (5Z,12E,14E)-11-Oxoprosta-5,9,12,14-tetraen-1-oic acid in synthesis. Common alternatives include other omega-9 fatty acids and their derivatives. Isomers and analogs such as (5Z,12E)- and (5Z,14E)-11-oxoprosta-5,9,12,14-tetraenoic acids are also used. Substitutes like prostaglandins and their synthetic analogs can be considered depending on the specific application.

The market for (5Z,12E,14E)-11-Oxoprosta-5,9,12,14-tetraen-1-oic acid is driven by increasing research in prostaglandin signaling pathways. Recent trends indicate growing interest in its potential therapeutic applications, particularly in inflammation and pain management. Market analysis suggests a steady demand with potential for growth in pharmaceutical and clinical research sectors.

Waste containing (5Z,12E,14E)-11-Oxoprosta-5,9,12,14-tetraen-1-oic acid (CAS: 87893-55-8) should be collected in appropriate containers and stored under safe conditions. For disposal, professional waste treatment facilities should be used. Environmental precautions include preventing leaks and ensuring proper incineration or chemical treatment to minimize environmental impact. Compliance with local regulations and obtaining necessary permits is crucial.